CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
病例报告：CD19 靶向 CAR-T 细胞治疗联合 BTK 抑制剂与 PD-1 抗体治疗继发性中枢神经系统淋巴瘤
英文原题：Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma.
查看英文原题
Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
未经标记：目前针对弥漫性大B细胞淋巴瘤（DLBCL）中枢神经系统（CNS）复发的治疗策略极为有限。继发性中枢神经系统淋巴瘤（SCNSL）也表现出严峻的预后和高死亡率。本报告描述了一名年轻女性DLBCL伴CNS复发患者，在接受多线化疗后，接受了低剂量CD19靶向CAR-T（CAR-T）细胞治疗，随后联合Bruton酪氨酸激酶抑制剂和程序性细胞死亡蛋白1抗体。然而，关于CAR-T 细胞治疗应用于SCNSL的报道有限，尤其是与靶向药物联合应用的情况。本病例的当前治疗组合为DLBCL的CNS复发提供了一种新方案。临床试验注册：ClinicalTrials.gov编号，NCT04666168。
展开英文摘要原文
UNLABELLED: Current therapeutic strategies for central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) are extremely limited. Secondary central nervous system lymphoma (SCNSL) also shows a grave prognosis and high mortality. This report describes a young female patient with DLBCL and CNS relapse who received low-dose CD19-directed chimeric antigen receptor T (CAR-T) cell therapy followed with Bruton's tyrosine kinase inhibitor and programmed cell death protein 1 antibody after several lines of chemotherapy.
However, limited reports on CAR-T cell therapy are applied for SCNSL, particularly those in combination with targeted agents. The current treatment combination for this case provides a new regimen for CNS relapse from DLBCL. CLINICAL TRIAL REGISTRATION: ClinicalTrials. gov number, NCT04666168.
论文信息
- 作者
- Zhang W、Huang C、Liu R、Zhang H、Li W、Yin S、Wang L、Liu W
- 单位
- Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.China
- 文献类型
- 病例报告 · 非美国政府资助研究
- 期刊
- Frontiers in immunology2022
- 原文标识
- PubMed 36275715 · DOI 10.3389/fimmu.2022.983934
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →